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n	 INTRODUCTION
Rheumatoid arthritis (RA) is the most common form of chronic infl amma-
tory rheumatism. This autoimmune disease 
leads to progressive joint damage, func-
tional disability, impaired quality of life 
and, in some cases, shortened life expec-
tancy (1, 2).
Several treatment options are available 
for patients with RA; however, none of 
them has a clear advantage over another 
(3). Traditional therapy for RA included 
corticosteroids and disease-modifying 
anti-rheumatic drugs (DMARDs), such 
as methotrexate, which slow down dis-
ease progression. More recently, biologic 
DMARDs specifi cally targeting cytokines, 
mainly Tumour Necrosis Factor (TNF), 
have been introduced. A large proportion 
of patients receiving these agents achieve 
moderate to good responses as defi ned by 
the European League Against Rheumatism 
(EULAR) criteria based on the Disease 
Activity Score (DAS-28) (4-8). Anti-TNF 
agents may improve symptoms of disease 
and physical function, and slow down joint 
damage (3, 9, 10). Moreover, this class of 
drugs is considered to be associated with 
an overall favorable tolerability profi le 
(9), even if patients treated with anti-TNF 
agents carry a slightly increased risk of 
opportunistic infections and, possibly, of 
lymphoma and other malignancies (11).
Clinical experience suggests that a consid-
erable proportion of patients does not show 
a sustained response or may not respond to 
anti-TNF therapy (11). As a consequence, 
dose escalations, drug switching or drug 
discontinuations because of lack of effi cacy 
are frequently reported (11-15); of these, 
drug discontinuations are of particular 
concern (11-15). In addition, drug discon-
tinuation can result from poor or absent tol-
erability (16). These modifi cations in treat-
ment regimens have also a direct impact on 
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RIASSUNTO
Questo studio osservazionale, condotto in 23 Centri italiani, descrive i pattern di trattamento con farmaci anti-
TNF in 703 pazienti affetti da artrite reumatoide, in un contesto di pratica clinica. 
Nel complesso, i risultati hanno mostrato come, a un follow-up di 36 mesi, un’elevata percentuale di pazienti 
debba interrompere il trattamento, con un potenziale impatto sulla spesa sanitaria. Inoltre, infliximab è stato 
associato a una maggiore incidenza di interruzioni del trattamento e di intensificazione del dosaggio rispetto a 
etanercept e adalimumab.
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annual cost as well as cost-effectiveness of 
these drugs, and this should be taken into 
account by health policy decision makers.
At present, data on dose escalation, drug 
switching or drug discontinuation of anti-
TNF agents in the Italian scenario are quite 
scant and were mainly collected in small 
observational studies or by the analysis of 
local registries (17-19). 
The aim of this observational study was to 
provide a description of real life treatment 
patterns of biologic anti-TNF, including 
the discontinuation rates, the dose changes 
and the frequency of switches in a large 
number of Italian Rheumatology centers in 
the Northern, Central and Southern areas 
of the Country.
n	 MATERIALS AND METHODS
Study design
This observational, multicenter, retrospec-
tive study was designed to evaluate Italian 
patients with RA. In total, 23 centers (9 in 
the Northern Italy, 10 in the Central Italy, 
and 4 in the Southern Italy) participated 
in this study. The study was assessed and 
approved by the local Ethics Committees 
of each centre and was conducted in accor-
dance with the Declaration of Helsinki. All 
patients provided written informed consent 
for their participation in the study.
In order to select a representative sample 
of patients, a chart review was performed 
and patients were recruited according to 
the following criteria:
a) >18 years of age;
b) diagnosis of RA (as defined by the 
American College of Rheumatology 
[ACR] revised criteria 1987);
c) treatement with the first biologic anti-
TNF agent between the 1st July 2002 to 
the 31st March 2004;
d) evaluation at the same center for at least 
12 months. Patients who were participat-
ing in other trials at the time of enroll-
ment or who had been included in other 
trials which involved dose modifications 
or dose maintenance with non-steroidal 
anti-inflammatory drugs (NSAIDs), 
corticosteroids, DMARDs or anti-TNF 
therapies in three years prior to enroll-
ment were excluded from the study. 
In total, patients underwent six visits dur-
ing the study period: baseline and at 3, 
6, 12, 24 and 36 months after initiating 
anti-TNF therapy (visits 1, 2, 3, 4 and 5, 
respectively). At baseline, inclusion and 
exclusion criteria, as well as baseline 
characteristics (demographics including 
body weight, duration of disease, DAS-28 
at diagnosis and at initiation of anti-TNF 
therapy, concentration of rheumatoid fac-
tor, radiographic alterations, last therapy 
administrated before the initiation of anti-
TNF therapy and EULAR classification) 
were collected. From visit 2, treatment dis-
continuations, dose changes and/or switch 
to another anti-TNF drug, were monitored 
and reasons for these decisions were re-
corded. Concomitant drug usage was also 
recorded. Depending on the drug adminis-
tered, dose escalation of anti-TNF agents 
was defined as follows:
1) intravenous infliximab administered at 
doses higher than 3 mg/kg or more fre-
quently than every eight weeks; 
2) subcutaneous etanercept administered 
more frequently than twice a week;
3) subcutaneous adalimumab administered 
at doses higher than 40 mg or adminis-
tered more frequently than every other 
week.
Study objectives
The primary objective of the study was 
to estimate the proportion of RA patients 
ever treated with an anti-TNF agent who 
discontinued therapy within 36 months of 
initiation and the reasons for discontinu-
ation. 
Secondary objectives included the as-
sessment of anti-TNF dosage patterns in 
patients remaining on their first biologic, 
considering the average dose and the pro-
portion of patients needing dose escalation 
and evaluating the costs associated, and the 
description of the proportion of patients 
switching to another anti-TNF drug.
Data analysis 
Baseline characteristics were stratified ac-
cording to anti-TNF agent, age, gender, 
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duration of follow-up, rheumatoid factor, 
EULAR classification, DAS-28, duration 
of disease, radiographic alteration and last 
therapy administrated before the initiation 
of anti-TNF therapy. Body weight was 
measured in the entire cohort and reported 
in terms of percent distribution of patients 
in predefined classes of weight.
The proportion of patients discontinuing 
therapy was evaluated using a Kaplan-
Meier survival analysis, where discontinu-
ation of therapy or switching to alternate 
therapy was considered an event. The dif-
ferences between the survival curves were 
assessed using the log-rank test, applying 
Bonferroni’s correction when appropriate. 
The reasons for discontinuation of therapy 
were stratified according to the drug at dif-
ferent timepoints. A Kaplan-Meier survival 
analysis was also used to evaluate modifi-
cations in dosage regimens where increas-
es in dose or frequency of administration 
were considered as events. Moreover, an 
evaluation of therapy costs (as available on 
December 2007) associated with these dos-
age modifications was performed.
Overall differences between drugs were 
assessed using the analysis of covari-
ance (ANCOVA) followed by the Tukey 
test for multiple comparisons (continuous 
variables) or the chi-square test applying 
Bonferroni’s correction when appropriate 
(categorical variables). 
A p value <0.05 was considered statisti-
cally significant.
n	 RESULTS
Baseline characteristics
In total, 703 patients (mean age 53.4±13.1 
years), of which 80.8% were female, were 
included in the observation. Data on body 
weight were available for 446 patients; 
body weight was distributed as follows: 
<60 kg, 29.8% (n=133), 60-70 kg, 39.5% 
Table I - Baseline characteristics of the patients involved in the study.
Total Infliximab Etanercept Adalimumab P value
Number of patients 703 248 (35.28%) 259 (36.84%) 196 (27.88%)
Age, years* 53.41 (13.09) 52.51 (13.26) 54.11 (13.78) 53.63 (11.88) 0.37
Males 135 (19.2%) 48 (19.35%) 54 (20.85%) 33 (16.84%) 0.56
Duration of observation, months* 39.71 (11.78) 39.31 (12.46) 38.75 (11.03) 41.49 (11.71) NA
Rheumatoid factor 
RF+
Total number of patients evaluated
256 (64.32%)
398 (100%)
75 (59.52%)
126 (100%)
95 (64.19%)
148 (100%)
86 (69.35%)
124 (100%)
0.27
EULAR classification
Good
Moderate
No
Total number of patients evaluated
7 (1.85%)
152 (40.10%)
220 (58.05%)
379 (100%)
0 (0.00%)
47 (38.52%)
75 (61.48%)
122 (100%)
2 (1.35%)
46 (31.08%)
102 (68.92%)
150 (100%)
5 (4.67%)
58 (55.14%)
43 (40.19%)
107 (100%)
<0.001
DAS-28*
Total number of patients evaluated
5.30 (1.21)
543
5.31 (1.10)
183
5.46 (1.21)
193
5.10 (1.29)
167 0.018
Duration of disease, years*
Total number of patients evaluated
9.33 (7.46)
670
9.64 (7.86)
235
9.92 (7.47)
243
8.19 (6.83)
192 0.04
Radiographic alterations
Yes
Total number of patients evaluated
456 (91.38%)
499 (100%)
150 (90.36%)
166 (100%)
186 (94.42%)
197 (100%)
120 (88.24%)
136 (100%)
0.12
Last therapy administrated
Only corticosteroids and/or NSAIDs
Also DMARDs
Total number of patients evaluated
91 (13.1%)
602 (86.9%)
693 (100%)
17 (7.00%)
225 (93.00%)
242 (100%)
49 (19.1%)
207 (80.9%)
256 (100%)
25 (12.8%)
170 (87.2%)
195 (100%)
0.0003
*mean ± (SD)
DAS-28 = Disease Activity Score; DMARDs = disease-modifying anti-rheumatic drugs; EULAR = European League 
Against Rheumatism; NSAID = non-steroidal anti-inflammatory drugs; RF = rheumatoid factor.
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(n=176), 71-80 kg, 21.1% (n=94), 81-90 
kg, 6.3% (n=28), 91-100 kg, 2.2%(n=10), 
and >100 kg, 1.1% (n=5). 
Baseline demographic characteristics are 
summarized in Table 1.
The mean duration of observation was 
slightly longer than 3 years (39.7±11.8 
months). Only 398 (56.6%) charts con-
tained data on rheumatoid factor; 256 
(64.3%) patients were positive for rheuma-
toid factor. The mean duration of RA was 
9.3±7.5 years. DAS-28 was 5.3±1.2 in 543 
(77.2%) patients for whom data were avail-
able. Only 379 (53.9%) patients were clas-
sified according to the EULAR criteria at 
baseline. 
Of these, 220 (58.1%) of patients were 
poor responders and 7 (1.8%) subjects 
were good responders to previous therapy.
Radiographic evaluations were reported 
in 456 (71.0%) patients, of whom 456 
(91.4%) showed alterations. 
Data regarding the last therapy prior to 
the initiation of anti-TNF was reported 
in 693 (98.6%) patients, of which 602 
(86.9%) were treated with DMARDs and 
91 (13.1%) were medicated with cortico-
steroid and/or NSAIDs therapy.
Stratification of baseline data according to 
anti-TNF agent showed that 248 (35.3%) 
patients were treated with infliximab, 259 
(36.8%) with etanercept and 196 (27.9%) 
with adalimumab. 
Significant differences between treatment 
groups were observed for EULAR classi-
fication, DAS-28, duration of disease and 
the last therapy administered before the ini-
tiation of anti-TNF therapy (Table I).
Proportion of patients discontinuing anti-
TNF therapy and reasons for discontinu-
ation
First course of therapy with infliximab was 
associated with lower cumulative drug sur-
vival than the other two agents (chi-square 
= 24.0, p<0.001), indicating a higher inci-
dence of discontinuation (Fig. 1). No dif-
ferences were observed between etanercept 
and adalimumab therapy in terms of drug 
survival. At 36 months, 74.7% of patients 
on etanercept, 72.0% of those on adalim-
umab and 57.7% of subjects receiving in-
fliximab were still on therapy. The discon-
tinuation rate of infliximab was statistically 
higher compared with either etanercept or 
adalimumab (p=0.0001 and p=0.0002, re-
spectively).
Overall, infliximab was associated with 
the highest incidence of discontinuation 
because of adverse events (14.5% vs 7.7% 
and 11.2 for etanercept and adalimumab, 
respectively; p=not significant) or insuffi-
cient response (20.2% vs 11.6% and 10.7 
for etanercept and adalimumab, respective-
ly; both p=0.01) at 36 months (Fig. 2).
Anti-TNF dosing patterns and associated 
costs 
Apart from one patient, all patients initi-
ated adalimumab therapy at a dose of 40 
mg, while 237 (91.5%), 21 (8.1%) and 1 
(0.4%) of patient(s) started etanercept ther-
apy at doses of 25, 50 and 20 mg, respec-
tively. None of the patients treated with 
adalimumab and 7 (2.7%) patients treated 
with etanercept required a dose escala-
tion. With regard to infliximab therapy, 155 
(62.4 %), 55 (22.3%) and 28 (11.3%) pa-
tients initiated therapy at doses of 3, 4 and 
5 mg/kg, respectively; 10 (4.0%) subjects 
initiated therapy at other dosages. Over-
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Figure 1 - Kaplan-Meier survival curve for 
infliximab, etanercept or adalimumab over a 
period of 36 months.
p<0.001 IFX vs ETA and ADA
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all, 54 (22.2%) patients receiving inflix-
imab therapy required a dosage escalation. 
Moreover, a dose escalation was required 
in more patients receiving infliximab 3 or 
4 mg/kg (27.9% and 16.5%, respectively) 
than those receiving other dosages (12.5%, 
3.6% and 0.0%, for patients receiving 2, 5 
and 6 mg/kg, respectively) of the drug.
Furthermore, a numerically higher propor-
tion of patients receiving infliximab com-
pared with etanercept or adalimumab ther-
apy required an increase in the frequency 
Figure 2 -  Incidence of discontinuation of therapy because of insufficient response or adverse 
events in patients receiving infliximab, etanercept or adalimumab at 36 months.
p=0.01 IFX vs ETA and ADA for insufficient response
Figure 3 - Incremental cost of different anti-TNF agents at 36 months when considering pa-
tients on their first biologic who required dose modification.
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of drug administration (11.3% vs 1.5% and 
5.6%, respectively), although a statistical 
analysis was not performed. Also, numeri-
cally more infliximab than etanercept or 
adalimumab recipients required a reduc-
tion in the frequency of administration 
(8.1% vs 6.6% and 0.5%, respectively); 
even in this case, a statistical analysis was 
not performed.
Taking into account changes in both 
dose and frequency of administration, at 
36-month of follow-up mean cost of treat-
ment per patient was € 28,186.60 (standard 
deviation, SD ±10,236.87) for infliximab, € 
36,541.16 (±10,603.65) for etanercept and 
€ 38,215.85 (±11,558.27) for adalimumab. 
In other terms, considering the entire pe-
riod of observation, the need for dose mod-
ification was associated with a 29.6% in-
cremental cost for infliximab, versus -2.1% 
and 4.4% for etanercept and adalimumab, 
respectively (Fig. 3), when compared with 
the approved therapeutic doses at the time 
of the observation.
Switching patterns
Switching patterns between anti-TNF 
drugs or between an anti-TNF agent and 
a conventional DMARD are summarized 
in Figure 4. Overall, 37.3%, 38.0%, and 
88.2% of patients switched from etaner-
cept, adalimumab, and infliximab therapy 
respectively to another anti-TNF agent.
Statistical analysis showed significant 
differences between the infliximab and 
etanercept (OR=12.5, Confidence Inter-
val 95%, CI 95%, 5.5-28.5; p<0.001) and 
Figure 4 - Switching patterns between anti-TNF drugs or between an anti-TNF agent and a 
conventional DMARD.
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Figure 5 - Kaplan-Meier survival curve for 
infliximab, etanercept or adalimumab as the 
second anti-TNF treatment over a total pe-
riod of 24 months.
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between the infliximab and adalimumab 
(OR=12.2, CI 95% 5.2-28.5; p<0.001) 
treatment groups, indicating that patients 
receiving infliximab therapy were more 
likely to switch to another anti-TNF agent 
than those receiving etanercept or adalim-
umab.
In total, patients discontinuing a first anti-
TNF agent and switching to a second one 
were 149: 12 switched to infliximab, 112 to 
etanercept, and 25 to adalimumab, respec-
tively. The survival rate of the second anti-
TNF agent, available over a 24-month pe-
riod, is shown in Figure 5. At 24 months of 
the second line treatment, 75%, 22%, and 
54% of infliximab, etanercept and adalim-
umab recipients, respectively, had discon-
tinued their second anti-TNF. Overall, the 
relative risk of discontinuing the second 
agent with respect to the first anti-TNF 
drug was 1.31 (CI 95% 0.96-1.83).
n	 DISCUSSION
The aim of this study was to describe the 
discontinuation rate and the different treat-
ment patterns of anti-TNF agents (adali-
mumab, etanercept and infliximab) in pa-
tients with RA in a large cohort of Italian 
patients treated in 23 Rheumatology cen-
ters from all areas of the Country. Over-
all, results presented here demonstrate a 
higher incidence of discontinuations and 
dose escalations in patients treated with 
infliximab compared with etanercept and 
adalimumab.
The National Institute for Health and Clini-
cal Excellence (NICE) updated guidelines 
for the treatment of RA (20) recommend 
adalimumab, etanercept and infliximab as 
options for adult patients with active RA 
(defined as DAS28 >5.1 points on two as-
sessments, 1 month apart) who have partic-
ipated in trials of two DMARDS, including 
methotrexate unless contraindicated. The 
NICE guidelines also recommended that 
continuation of anti-TNF treatment should 
only occur if there is an adequate response 
at 6 months follow-up (defined as improve-
ment in DAS28 ≥1.2 points) with further 
monitoring at a minimum of 6-monthly in-
tervals and treatment withdrawal if an ad-
equate response is not maintained. 
Discontinuation of anti-TNF therapy has 
been extensively investigated in recent 
years (7, 8, 15-19). However, results have 
been generally inconclusive: in some stud-
ies the incidence of discontinuation was 
higher in patients with RA or spondyloar-
thropathies receiving infliximab compared 
with those receiving etanercept or adali-
mumab therapy (7, 15), but these findings 
were challenged (16). 
In our study, the discontinuation rates asso-
ciated with the three drugs were generally 
similar to those reported in studies evaluat-
ing patients with RA or spondyloarthropa-
thies, some of which were conducted in the 
Italian scenario (7, 17-19, 21-23). Overall, 
infliximab was associated with a higher 
discontinuation rate than the other anti-
TNF agents. 
The most important reasons for discontinu-
ation of therapy in the present study were 
the occurrence of insufficient response to 
therapy and of adverse events, which were 
observed, at different rates, with all anti-
TNF agents. A higher proportion of pa-
tients treated with infliximab discontinued 
therapy because of an insufficient response 
to treatment. These results are in line with 
other studies, which showed that insuf-
ficient response was the most important 
reason for discontinuation of therapy after 
one year of infliximab treatment (21, 24). 
Moreover, there was a trend towards more 
discontinuations because of adverse events 
associated with infliximab than etanercept 
or adalimumab therapy.
Data in the literature also suggest that 
patients receiving infliximab frequently 
require dose escalations to achieve a re-
sponse (7, 14, 25) and similar results have 
been reported in Italy (17). In contrast, 
studies suggested that dose escalations 
were less frequent with etanercept and 
adalimumab than infliximab therapy (7, 
14). Data in the present study support these 
findings and show a significantly higher in-
cidence of dose escalations with infliximab 
than with etanercept or adalimumab at 36 
months. Similar results were observed with 
respect to the frequency of administration. 
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It must be observed, however, that a statis-
tical analysis was not performed for these 
two parameters, and therefore these results 
should be regarded as indicative and not 
definite findings.
Of note, drug discontinuations, dosage 
adjustments and the need to switch to an-
other anti-TNF agent may pose important 
concerns from a pharmacoeconomic per-
spective. In our study, the evaluation of 
total costs (including incremental costs) 
associated with different anti-TNF agents 
suggested that these drugs present an over-
all similar impact to healthcare expense. 
In fact, although infliximab is associated 
to the lowest mean cost when compared to 
etanercept and adalimumab, the frequent 
need for dose adjustments with this drug 
accounts for a higher incremental cost.
Data from our study regarding switching to 
an alternative anti-TNF agent are of partic-
ular interest. Most patients switched from 
infliximab to etanercept (65.6%), with few-
er patients (18.3%) switching to DMARDs 
other than anti-TNF agents. These results 
are overall similar to those reported in the 
literature (26,27), although some authors 
have also suggested a switch from inflix-
imab to adalimumab (28, 29). 
One surprising finding of this study is the 
relatively low proportion of patients for 
whom an assessment of the RF status was 
available (56.6%): according to this result, 
in Italy the evaluation of RF in clinical 
practice is still suboptimal.
It must be acknowledged that this is an ob-
servational study and therefore may only 
infer associations, and not cause-effect re-
lationships, which can be only addressed 
by a randomized trial. However, the precise 
aim of this analysis was to evaluate anti-
TNF patterns of usage in a real-life sce-
nario, since data on discontinuation, dose 
adjustments of and switch between differ-
ent anti-TNF agents are unlikely to be re-
trieved from randomized trials (11). 
Moreover, our analysis reports the results 
of a large observational study, with well-
defined inclusion and exclusion criteria: 
we speculate that a similar design may 
strengthen the overall validity of the result-
ing evidence.
Conclusions and possible implications for 
clinical practice
The results of this large multicenter ob-
servational study, conducted in a real-life 
scenario, suggest that anti-TNF agents 
may be associated with a rather high inci-
dence of discontinuation and dose adjust-
ments over a 36-month period in patients 
with rheumatoid arthritis, with a possible 
effect on healthcare expense. In particular, 
infliximab appeared to be associated with 
a higher incidence of discontinuations and 
dose escalations, compared with etanercept 
and adalimumab.
Taking these findings together, we specu-
late that other therapeutic options with a 
different mechanism of action (e.g. abata-
cept, rituximab, and tocilizumab) should be 
considered in clinical practice, in particular 
in patients who fail the first anti-TNF treat-
ment (11). Such an approach was recently 
acknowledged in the new EULAR recom-
mendations for the management of RA that 
report the high level of evidence (RCTs) 
supporting other mechanisms of action 
than TNF antagonism as valid treatment 
choices as of first anti-TNF insufficient 
response (30). In particular, evidence sug-
gests that abatacept may be a cost-effective 
strategy in patients discontinuing anti-TNF 
agents (31, 32). This finding has been very 
recently strengthened by the results of a 
cost-effectiveness study, conducted in the 
US, which underlined the cost-effective-
ness of abatacept, when compared to ritux-
imab, in patients affected by rheumatoid 
arthritis (33). Similar pharmacoeconomic 
evaluations concerning the Italian reality 
are ongoing and will likely shed new lights 
on the cost-effectiveness of these new mol-
ecules (manuscript in preparation).
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SUMMARY
Objective: This study aims to provide a description of real life treatment patterns of biologic anti-TNF in 23 
Italian Rheumatology centers.
Methods: This was an observational, multicenter, retrospective study. Patients >18 years of age, diagnosed 
with rheumatoid arthritis and treated with the ­ rst biologic anti-TNF agent between the 1st July 2002 to the 
31st March 2004 were included. Total follow-up was 36 months.
Results: In total, 248 patients were ­ rst treated with in iximab, 259 with etanercept and 196 with adalimumab. 
First course of therapy with in iximab was associated with lower cumulative drug survival than the other two 
agents. At 36 months, 74.7% of patients on etanercept, 72.0% of those on adalimumab and 57.7% of subjects 
receiving in iximab were still on therapy. 
In total, 149 patients switched to a second anti-TNF agent. At 24 months of the second line treatment, 75%, 
22%, and 54% of in iximab, etanercept and adalimumab recipients, respectively, had discontinued their second 
anti-TNF. 
Conclusions: Anti-TNF agents may be associated to a rather high incidence of discontinuation and dose ad-
justments over a 36-month period, with a possible effect on healthcare expense. In particular, in iximab was 
associated with a higher incidence of discontinuations compared with etanercept and adalimumab.
Parole chiave: Anti-TNF; artrite reumatoide; pattern di trattamento.
Key words: Anti-TNF; rheumatoid arthritis; treatment patterns.
Reumatismo1/2011	 27
LAVORO
ORIGINALETreatment	Patterns	of	Anti-TNF	Agents	in	Italy:	an	observational	study
n	 REFERENCES
1.	American	College	of	Rheumatology	Subcom-
mittee	 on	 Rheumatoid	 Arthritis	 Guidelines.	
Guidelines	for	the	management	of	rheumatoid	
arthritis:	2002	Update.	Arthritis	Rheum	2002;	
46:	328-46.
2.	Luqmani	R,	Hennell	S,	Estrach	C,	Birrell	F,	
Bosworth	A,	Davenport	G,	et	al;	British	Soci-
ety	for	Rheumatology;	British	Health	Profes-
sionals	 in	 Rheumatology	 Standards,	 Guide-
lines	and	Audit	Working	Group.	British	Soci-
ety	for	Rheumatology	and	British	health	pro-
fessionals	in	Rheumatology	guideline	for	the	
management	of	rheumatoid	arthritis	(the	first	
two	years).	Rheumatology	(Oxford)	2006;	45:	
1167-9.
3.	Donahue	 KE,	 Gartlehner	 G,	 Jonas	 DE,	 Lux	
LJ,	Thieda	P,	 Jonas	BL,	et	 al.	Systematic	 re-
view:	comparative	effectiveness	and	harms	of	
disease-modifying	medications	for	rheumatoid	
arthritis.	Ann	Intern	Med	2008;	148:	124-34.
4.	Bennett	AN,	Peterson	P,	Zain	A,	Grumley	 J,	
Panayi	G,	Kirkham	B.	Adalimumab	in	clinical	
practice.	Outcome	 in	70	 rheumatoid	 arthritis	
patients,	 including	 comparison	 of	 patients	
with	and	without	previous	anti-TNF	exposure.	
Rheumatology	(Oxford)	2005;	44:	1026-31.
5.	Feltelius	N,	Fored	CM,	Blomqvist	P,	Bertils-
son	L,	Geborek	P,	Jacobsson	LT,	Lindblad	S,	
et	 al;	ARTIS	Group.	 Results	 from	 a	 nation-
wide	postmarketing	cohort	study	of	patients	in	
Sweden	 treated	with	etanercept.	Ann	Rheum	
Dis	2005;	64:	246-52.
6.	Hyrich	 KL,	 Symmons	 DP,	Watson	 KD,	 Sil-
man	AJ;	British	Society	for	Rheumatology	Bi-
ologics	Register.	Comparison	of	the	response	
to	infliximab	or	etanercept	monotherapy	with	
the	 response	 to	 cotherapy	with	methotrexate	
or	 another	 disease-modifying	 antirheumatic	
drug	in	patients	with	rheumatoid	arthritis:	re-
sults	from	the	British	Society	for	Rheumatol-
ogy	Biologics	Register.	Arthritis	Rheum	2006;	
54:	1786-94.
7.	Finckh	A,	 Simard	 JF,	Gabay	C,	Guerne	 PA;	
SCQM	 physicians.	 Evidence	 for	 differential	
acquired	drug	resistance	to	anti-tumour	necro-
sis	 factor	agents	 in	rheumatoid	arthritis.	Ann	
Rheum	Dis	2006;	65:	746-52.
8.	Strangfeld	A,	Hierse	F,	Kekow	J,	von	Hinue-
ber	U,	Tony	HP,	Dockhorn	R,	et	al.	Compara-
tive	 effectiveness	 of	 TNFalpha	 inhibitors	 in	
combination	with	either	methotrexate	or	leflu-
nomide.	Ann	Rheum	Dis	2009;	68:	1856-62.
9.	Chen	YF,	 Jobanputra	 P,	 Barton	 P,	 Jowett	 S,	
Bryan	S,	Clark	W,	et	al.	A	systematic	review	
of	the	effectiveness	of	adalimumab,	etanercept	
and	infliximab	for	the	treatment	of	rheumatoid	
arthritis	in	adults	and	an	economic	evaluation	
of	their	cost-effectiveness.	Health	Technol	As-
sess	2006;	10:	iii-iv,	xi-xiii,	1-229.
10.	van	Riel	PL,	Taggart	AJ,	Sany	J,	Gaubitz	M,	
Nab	HW,	Pedersen	R,	et	al;	Add	Enbrel	or	Re-
place	Methotrexate	Study	 Investigators.	Effi-
cacy	and	safety	of	combination	etanercept	and	
methotrexate	 versus	 etanercept	 alone	 in	 pa-
tients	with	rheumatoid	arthritis	with	an	inad-
equate	response	to	methotrexate:	the	ADORE	
study.	Ann	Rheum	Dis	2006;	65:	1478-83.
11.	Rubbert-Roth	A,	Finckh	A.	Treatment	options	
in	 patients	 with	 rheumatoid	 arthritis	 failing	
initial	TNF	inhibitor	therapy:	a	critical	review.	
Arthritis	Res	Ther.	2009;	11	(Suppl.	1):	S1.
12.	van	 Vollenhoven	 R,	 Harju	 A,	 Brannemark	
S,	 Klareskog	 L.	 Treatment	 with	 infliximab	
(Remicade)	 when	 etanercept	 (Enbrel)	 has	
failed	 or	 vice	 versa:	 data	 from	 the	 STURE	
registry	showing	that	switching	tumour	necro-
sis	factor	alpha	blockers	can	make	sense.	Ann	
Rheum	Dis	2003;	62:	1195-8.
13.	Nikas	SN,	Voulgari	PV,	Alamanos	Y,	Papado-
poulos	 CG,	Venetsanopoulou	AI,	 Georgiadis	
AN,	 et	 al.	 Efficacy	 and	 safety	 of	 switching	
from	 infliximab	 to	 adalimumab:	 a	 compara-
tive	 controlled	 study.	Ann	Rheum	Dis	 2006;	
65:	257-60.
14.	Ariza-Ariza	 R,	 Navarro-Sarabia	 F,	 Hernán-
dez-Cruz	B,	Rodríguez-Arboleya	L,	Navarro-
Compán	V,	 Toyos	 J.	 Dose	 escalation	 of	 the	
anti-TNF-alpha	 agents	 in	 patients	with	 rheu-
matoid	 arthritis.	A	 systematic	 review.	 Rheu-
matology	(Oxford)	2007;	46:	529-32.
15.	Brocq	 O,	 Roux	 CH,	 Albert	 C,	 Breuil	 V,	
Aknouche	N,	Ruitord	S,	et	al.	TNFalpha	an-
tagonist	continuation	rates	in	442	patients	with	
inflammatory	joint	disease.	Joint	Bone	Spine	
2007;	74:	148-54.
16.	Duclos	 M,	 Gossec	 L,	 Ruyssen-Witrand	 A,	
Salliot	C,	Luc	M,	Guignard	S,	et	al.	Retention	
rates	of	tumor	necrosis	factor	blockers	in	daily	
practice	in	770	rheumatic	patients.	J	Rheuma-
tol	2006;	33:	2433-8.
17.	Favalli	EG,	Marchesoni	A,	Colombo	GL,	Sin-
igaglia	L.	Pattern	of	use,	economic	burden	and	
vial	optimization	of	infliximab	for	rheumatoid	
arthritis	 in	 Italy.	 Clin	 Exp	 Rheumatol	 2008;	
26:	45-51.
18.	Caporali	R,	Sarzi-Puttini	P,	Atzeni	F,	Gorla	R,	
Filippini	M,	Marchesoni	A,	 et	 al.	 Switching	
TNF-alpha	 antagonists	 in	 rheumatoid	 arthri-
tis:	The	experience	of	the	LORHEN	registry.	
Autoimmun	Rev	2010;	9:	465-69.
19.	Marchesoni	A,	Zaccara	E,	Gorla	R,	Bazzani	C,	
Sarzi-Puttini	P,	Atzeni	F,	et	al.	TNF-alpha	an-
tagonist	survival	rate	in	a	cohort	of	rheumatoid	
arthritis	patients	observed	under	conditions	of	
standard	clinical	practice.	Ann	N	Y	Acad	Sci	
2009;	1173:	837-46.
20.	NICE	 (2007).	 “National	 Institute	 for	 Health	
and	 Clinical	 Excellence	 (NICE)	 technology	
appraisal	 guidance	130	 (TA130).	Adalimum-
ab,	etanercept	and	infliximab	for	the	treatment	
of	 rheumatoid	 arthritis.	 Includes	 a	 review	 of	
technology	appraisal	guidance	36.	Issue	date:	
28	 Reumatismo	1/2011
L. Punzi, M. Matucci Cerinic, F. Cantini, et al.
LAVORO
ORIGINALE
October 2007. Available at: http://www.nice.
org.uk/nicemedia/pdf/TA130guidance.pdf.”
21. Gomez-Reino JJ, Carmona L; BIOBADASER 
Group. Switching TNF antagonists in patients 
with chronic arthritis: an observational study 
of 488 patients over a four-year period. Arthri-
tis Res Ther 2006; 8: R29.
22. Kvalvik AG, Lefsaker L, Dyvik S, Brun JG. 
Anti-tumor necrosis factor-alpha therapy in 
the ordinary clinical setting: Three-year effec-
tiveness in patients with rheumatoid arthritis. 
Joint Bone Spine 2007; 74: 606-11.
23. Genta MS, Kardes H, Gabay C. Clinical eval-
uation of a cohort of patients with rheumatoid 
arthritis treated with anti-TNF-alpha in the 
community. Joint Bone Spine 2006; 73: 51-6.
24. Du Pan SM, Dehler S, Ciurea A, et al; on be-
half of the Swiss Clinical Quality Management 
Physicians. Comparison of Drug Retention 
Rates and Causes of Drug Discontinuation 
Between Anti–Tumor Necrosis Factor Agents 
in Rheumatoid Arthritis. Arthritis & Rheuma-
tism. Arthritis Care Res 2009; 61: 560-8.
25. Durez P, Van den Bosch F, Corluy L, Veys EM, 
De Clerck L, Peretz A, et al. A dose adjust-
ment in patients with rheumatoid arthritis not 
optimally responding to a standard dose of 
infliximab of 3 mg/kg every 8 weeks can be 
effective: a Belgian prospective study. Rheu-
matology (Oxford) 2005; 44: 465-8.
26. Buch MH, Bingham SJ, Bejarano V, Bryer D, 
White J, Reece R, et al. Therapy of patients 
with rheumatoid arthritis: outcome of inflix-
imab failures switched to etanercept. Arthritis 
Rheum 2007; 57: 448-53.
27. Iannone F, Trotta F, Montecucco C, Giacome-
lli R, Galeazzi M, Matucci-Cerinic M, Ferri C, 
et al; GISEA (Gruppo Italiano per lo Studio 
delle Early Arthritis). Etanercept maintains 
the clinical benefit achieved by infliximab in 
patients with rheumatoid arthritis who discon-
tinued infliximab because of side effects. Ann 
Rheum Dis 2007; 66: 249-52.
28. Bombardieri S, Ruiz AA, Fardellone P, Geu-
sens P, McKenna F, Unnebrink K, et al; Re-
search in Active Rheumatoid Arthritis (ReAct) 
Study Group. Effectiveness of adalimumab for 
rheumatoid arthritis in patients with a history 
of TNF-antagonist therapy in clinical practice. 
Rheumatology (Oxford) 2007; 46: 1191-9.
29. Walsh CA, Minnock P, Slattery C, Kennedy N, 
Pang F, Veale DJ, et al. Quality of life and eco-
nomic impact of switching from established 
infliximab therapy to adalimumab in patients 
with rheumatoid arthritis. Rheumatology (Ox-
ford) 2007; 46: 1148-52.
30. Smolen JS, Landewé R, Breedveld FC, Dou-
gados M, Emery P, Gaujoux-Viala C, et al. 
EULAR recommendations for the manage-
ment of rheumatoid arthritis with synthetic 
and biological disease-modifying antirheu-
matic drugs. Ann Rheum Dis 2010; 69: 964-
75.
31. Russell A, Beresniak A, Bessette L, Haraoui 
B, Rahman P, Thorne C, et al. Cost-effec-
tiveness modeling of abatacept versus other 
biologic agents in DMARDS and anti-TNF 
inadequate responders for the management of 
moderate to severe rheumatoid arthritis. Clin 
Rheumatol 2009; 28: 403-12.
32. Vera-Llonch M, Massarotti E, Wolfe F, Shad-
ick N, Westhovens R, Sofrygin O, et al. Cost-
effectiveness of abatacept in patients with 
moderately to severely active rheumatoid ar-
thritis and inadequate response to tumor ne-
crosis factor-alpha antagonists. J Rheumatol 
2008; 35: 1745-53.
33. Yuan Y, Trivedi D, Maclean R, Rosenblatt L. 
Indirect cost-effectiveness analyses of abata-
cept and rituximab in patients with moderate-
to-severe rheumatoid arthritis in the United 
States. J Med Econ 2010; 13: 33-41. 
